Perioperative Risks of Concurrent Pancreatic and Hepatic Resections for Neuroendocrine Tumors
Open Access
- 6 August 2026
- journal article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 134 (6) , 830-839
Abstract
Background and Objectives: Pancreatic neuroendocrine tumors (pNETs) account for 1%–2% of pancreatic tumors, with an increasing incidence. The safety of concurrent pancreas‐liver resections remains uncertain. This study evaluated the national outcomes of concurrent pancreatectomy and liver‐directed surgery for pNETs. Methods: ACS‐NSQIP (2019–2023) was queried for adult patients who underwent pancreatectomy for pNETs. Concurrent liver‐directed procedures were identified by CPT code and classified as hepatectomy or ablation alone; patients were grouped as isolated pancreatectomy, concurrent hepatectomy, or concurrent ablation alone. Pre‐, intra‐, and postoperative characteristics were compared using inferential statistics. Multivariable logistic regression identified predictors of 30‐day morbidity, readmission, reoperation, and mortality, with Firth penalized likelihood used for rare outcomes. Results: Of 4794 patients, 4587 (95.7%) underwent isolated pancreatectomy, 172 (3.6%) underwent concurrent hepatectomy, and 35 (0.7%) underwent concurrent ablation alone. Concurrent hepatectomy was parenchymal‐sparing in 163 of 172 patients (94.8%); only nine patients underwent a major hepatectomy. Overall morbidity was similar across groups (38.8%, 45.9%, and 42.9%; p = 0.154), as was serious morbidity (28.7%, 27.9%, 22.9%; p = 0.730) and 30‐day mortality (1.0%, 0.6%, 0%). On multivariable analysis, neither concurrent hepatectomy (OR 1.02, 95% CI 0.71–1.48) nor concurrent ablation (OR 0.94, 95% CI 0.46–1.93) was associated with morbidity. Pancreatoduodenectomy was associated with morbidity (OR 2.38, 95% CI 2.05–2.76), reoperation (OR 2.16, 95% CI 1.52–3.08), and mortality (OR 2.50, 95% CI 1.39–4.50), and a minimally invasive approach was associated with lower morbidity (OR 0.69, 95% CI 0.60–0.80). Conclusions: Concurrent liver‐directed surgery was not associated with an increase in 30‐day morbidity or mortality after pancreatectomy for pNETs. These findings support the safety of concurrent hepatic resection in appropriately selected pNET patients.Keywords
This publication has 22 references indexed in Scilit:
- The morbidity of simultaneous pancreatic and liver resection for metastatic pancreatic neuroendocrine tumorsJournal of Gastrointestinal Surgery, 2025
- Prognosis of small pancreatic neuroendocrine neoplasms: Functionality mattersThe American Journal of Surgery, 2025
- Comparative outcomes of pancreatic neuroendocrine neoplasms: A population-based analysis of the SEER databaseEuropean Journal of Surgical Oncology, 2022
- Surgery vs Observation for Patients With Small Pancreatic Neuroendocrine TumorsJAMA Surgery, 2021
- Do somatostatin-analogues have the same impact on postoperative morbidity and pancreatic fistula in patients after pancreaticoduodenectomy and distal pancreatectomy? – A systematic review with meta-analysis of randomized-controlled trialsPancreatology, 2020
- Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine TumorsJAMA Network Open, 2020
- The epidemiology of metastases in neuroendocrine tumorsInternational Journal of Cancer, 2016
- Recommendations for management of patients with neuroendocrine liver metastasesThe Lancet Oncology, 2014
- Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survivalAnnals of Oncology, 2008
- Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: A 15-year single center prospective studySurgery, 2003